Polyphor valuation report “Ride the balixafortide” & “FORTRESS”

Monday, March 29, 2021 @ 12:00 am

Critical phase III FORTRESS trial balixafortide in mBC remains on track to report results in 2021.
Up to CHF 24 mn grants awarded from CARB-X and CFF to support development of new antibiotic programs and inhaled murepavadin.
New CXCR4 lead compound announced and new “wild card” COVID-19 indication for balixafortide.

Key catalysts
Balixafortide pivotal phase III “FORTRESS” ORR results (Q2 2021)
New CXCR4 lead candidate (Q2 2021)
Balixafortide pivotal phase III “FORTRESS” PFS results (Q4 2021)

Go to the Polyphor Valuation Report

You may also be interested in

ten23 health and Ypsomed collaborate on the commercialization of patch injector

ten23 health and Ypsomed today announced that they are entering into a strategic partnership to advance the commercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses.
April 16, 2024

Orio Therapeutics raises CHF 500,000 for cardioprotective therapy development

Orio Therapeutics secures CHF 500,000 pre-seed funding to fuel the development of cardioprotective therapy for heart attack patients.
April 4, 2024

Newron valuation report "A pivotal year"

March 26, 2024

Stämm scales adherent cells by leveraging 3D printing and microfluidics

March 25, 2024

ten23 health: Partnership with SHL Medical

ten23 health, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, and SHL Medical, a world-leading provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
March 25, 2024

InSphero unveils promising tool for MASH drug discovery

March 22, 2024